Haloperidol plasma levels and clinical response in paranoid schizophrenics

Publisher Website
Google Scholar
Abstract
The relationship between haloperidol plasma levels, plasma prolactin, and therapeutic efficacy was evaluated in 20 paranoid schizophrenics in a fixed-dose study for 6 weeks. We found a significant intrapatient cross-correlation of therapeutic efficacy, as measured by decrease in MSS and BPRS rating scales and time-dependent haloperidol and pro lactin changes, which were tested at weekly intervals. However, no significant curvilinear relationship was present between steady-state haloperidol plasma levels and MSS and BPRS improvement scores. Our data do not furnish clear-cut evidence in favor of the existence of a therapeutic window for haloperidol plasma levels in paranoid schizophrenia.